Royalty Report: Drugs, Drug Discovery, ribonucleic acid – Collection: 344587

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Drug Discovery
  • ribonucleic acid
  • Cancer
  • Respiratory
  • Delivery
  • Medical
  • DNA
  • Disease
  • Genome
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 344587

License Grant
Licensor grants to the Canadian Licensee an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and under the Licensor Core Technology Patents, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import Products.
License Property
Licensor is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to identify and commercialize novel drugs.

Antisense Compound means an oligomeric compound or analog, mimic or mimetic thereof having a sequence that is partially or wholly complementary to the sequence of a messenger RNA (pre-mRNA or mRNA), viral RNA, or noncoding RNA that directly modulates RNA expression.

Product means a pharmaceutical preparation comprising any single TS ASO or Tandem selected by Licensee. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each TS ASO which constitutes the active pharmaceutical ingredient in each Product.

TS ASO means a single-stranded oligonucleotide or an analog thereof that hybridizes to TS mRNA using Watson-Crick base pairing and inhibits production of TS via an RNase-H mechanism.

1. U.S. Patent No. 6,001,1653
2. PCT Publication No. WO 93/13121
3. U.S. Patent. 5,914,396
4. U.S. Patent 61451,991
5. U.S. Patent No. 6,166,197
6. U.S. Patent No. 51919,619
7. U.S. Patent No. 5,962,425
8. U.S. Patent No. 6,143,881
9. U.S. Patent No. 5,969,116
10. U.S. Patent No. 6,346,614
11. U.S. Patent No. 6,399,754
12. U.S. Patent No. 6,326,199

Field of Use
The field of use is the identification of a lead TS ASO targeted to inhibit Thymidylate Synthase.

The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies, antisense inhibition of TS suppressed human tumor cell growth and overcame tumor cell resistance to marketed TS-targeted drugs.

TS is an important target in a wide variety of cancers including, colorectal, breast, stomach, esophageal, head and neck cancers, and mesothelioma; it is of increasing importance in non-small cell lung cancer. In addition to interfering with the effectiveness of chemotherapy, the TS gene may also participate in causing cancer. TS is a target for several chemotherapy agents, including 5-fluorouracil (5-FU), pemetrexed (Alimta®), and raltitrexed (Tomudex®).

IPSCIO Record ID: 301257

License Grant
Licensor and Licensee will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensor-Licensee Exclusive Targets and the Licensee Exclusive Targets. For each Licensor-Licensee Exclusive Target, Licensee will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensor and Licensee will identify and develop Splicing Modulators that modulate the splicing of Licensor-Licensee Exclusive Targets and Licensee Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants to Licensee an exclusive worldwide license to the Splicing Patents solely to research, develop, make and have made, offer for sale, sell, import and export Licensee Exclusive Products.

License Property
Product means an Licensor-Licensee Exclusive Product or an Licensee Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensee owns or controls certain patents related to morpholino chemistry.

Licensor-Licensee Exclusive Product means a Splicing Modulator that modulates an Licensor-Licensee Exclusive Target and that is Covered by the Licensee Patents and/or an Licensor Invention Patent.

Licensee Exclusive Product means a Splicing Modulator that modulates an Licensee Exclusive Target and is Covered by the Splicing Patents and/or an Licensee Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensee Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensor Splicing Patents.

Licensor Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensee Invention Patent and/or Licensor Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensor Invention or an Licensee Invention, as the case may be, and Patents claiming such Inventions will be Licensor Invention Patents or Licensee Invention Patents, respectively.

Licensor-Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 291167

License Grant
Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensee and Licensor will identify and develop Splicing Modulators that modulate the splicing of Licensee-Licensor Exclusive Targets and Licensor Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants Licensee the following licenses
Licensor grants Licensee an exclusive worldwide license to the Licensor Patents solely to research, develop, offer for sale, sell, import and export Licensee-Licensor Exclusive Products.

License Property
Product means an Licensee-Licensor Exclusive Product or an Licensor Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensor owns or controls certain patents related to morpholino chemistry.

Licensee-Licensor Exclusive Product means a Splicing Modulator that modulates an Licensee-Licensor Exclusive Target and that is Covered by the Licensor Patents and/or an Licensee Invention Patent.

Licensor Exclusive Product means a Splicing Modulator that modulates an Licensor Exclusive Target and is Covered by the Splicing Patents and/or an Licensor Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensor Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensee Splicing Patents.

Licensee Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensor Invention Patent and/or Licensee Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensee Invention or an Licensor Invention, as the case may be, and Patents claiming such Inventions will be Licensee Invention Patents or Licensor Invention Patents, respectively.

Licensee-Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 329733

License Grant
Licensor shall grant to Licensee the option with respect to Reagent Targets ( each, an Licensee Option) to obtain a non-exclusive, royalty-bearing license, including the right to sublicense, under the Licensor Non-Collaboration ASO Patent Rights to develop, make, have made, use, import, offer for sale and sell Licensee Non-Collaboration ASO Products directed to such Reagent Target in the Territory..
License Property
Licensor Non-Collaboration ASO Patent Right means all Patent Rights that are Controlled by Licensor, or any Sublicensees to whom Licensor provides data generated from the use of a Reagent ASO Compound provided to Licensor by Licensee pursuant to this Agreement and that (a) Cover inventions made by Licensor or such Sublicensee outside the course of the Collaboration and (b) either (i) include in their written specifications a description of the results of any experiment conducted using a Reagent ASO Compound provided to Licensor by Licensee pursuant to this agreement or (ii) are or were prosecuted (i.e., the results of any experiment conducted using Reagent ASO Compound provided to Licensor by Licensee pursuant to this Agreement were provided to patent office during the prosecution phase of a particular Patent Right) using any portion of the results of any experiment conducted using a Reagent ASO Compound provided to Licensor by Licensee pursuant to this Agreement.

Reagent ASO Compound means all ASO Compounds that selectively modulate protein synthesis of a Reagent Target.

ASO Compound means an oligonucleotide or an analog thereof (an oligonucleotide) that selectively modulates protein synthesis at the nucleic acid level through the binding of such oligonucleotide to a complementary sequence.

Reagent Target means a Target that is designated a Reagent Target by Licensor; provided, however, that a Reagent Target that is later designated a Validation Target or a Drug Discovery Target shall not be considered a Reagent Target after the date of such designation.

Drug Discovery Target means any Target included in the Antisense Drug Discovery Program by the Executive Committee.

Antisense Drug Discovery Program means the program of research and development of Drug Discovery ASO Compounds and Products in the Collaborative Therapeutic Areas under this Agreement and the Collaborative Research Plan.

Drug Discovery ASO Product means any preparation in final form for sale by prescription, over-the-counter or any other method for any indication, including human or animal use, which contains one or more Drug Discovery ASO Compounds.

Drug Discovery ASO Compound means an ASO Compound that selectively modulates protein synthesis of a Drug Discovery Target.

Validation Target means any Target designated by Licensor for inclusion in the Target Validation Program; provided, however, that a Validation Target that is later designated a Drug Discovery Target, shall be considered a Drug Discovery Target and not a Validation Target. Validation Targets includes Accepted Validation Targets and Rejected Validation Targets.

Target means a transcriptional unit of a gene, and any protein product of such transcriptional unit, including all splice variants.

Field of Use
Field of use is for use in gene functionalization and target validation and as therapeutic products in the field of antisense technology, including processes and techniques relating to the design, synthesis and research of antisense oligonucleotides.

Non-ASO Field means the research, development, manufacture and sale of compounds other than ASO Compounds as therapeutic or prophylactic pharmaceutical products.

ASO Field means the development, manufacture and sale of ASO Products as therapeutic or prophylactic pharmaceutical products.

IPSCIO Record ID: 367330

License Grant
Licensor hereby grants to Canadian Licensee (a) an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and (b) a non-exclusive, worldwide license under the Licensor Core Technology Patents, both licenses solely to develop, make, have made, use, sell, offer for sale, have sold and import Products. The licenses granted to Licensee are sublicensable only in connection with a license of Products to a Third Party for the continued development and commercialization of Products in accordance with the terms of this Agreement.
License Property
Product means a pharmaceutical preparation comprising any single antisense inhibitor generated under the Project Plan which down regulates IGFBP-5 and/or IGFBP-2. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each antisense inhibitor which constitutes the active pharmaceutical ingredient in each Product.

IGFBP-5 means the gene target Insulin-like Growth Factor Binding Protein 5.

IGFBP-2 means the gene target Insulin-like Growth Factor Binding Protein 2.

Product-Specific Technology means any discovery, device, process, method of use, composition, or formulation, whether or not patented or patentable, which is made or Controlled solely by Licensor or Licensee, or jointly by Licensor and Licensee, prior to the Effective Date or during the Term of this Agreement, and which relates only to the gene targets down regulated by a Product.

The compound is the first bi-specific antisense inhibitor, a single-stranded antisense drug designed to inhibit the production of two proteins simultaneously, to enter into preclinical development. OGX-225 targets both insulin-like growth factor binding protein- 5 (IGFBP-5) and insulin-like growth factor binding protein-2 (IGFBP-2), two molecules involved in the development of metastatic disease in hormone- regulated tumors such as prostate and breast cancers. Specific financial terms of the deal were not disclosed.

Field of Use
Field of use is for cancer therapies that address treatment resistance in cancer patients.

OGX-225 could prove effective as a therapeutic to prevent progression of prostate cancer and other tumor types.

The therapies are focused on reducing the production of both insulin-like growth factor binding protein-2 (IGFBP-2) and insulin-like growth factor binding protein-5 (IGFBP-5) with a single product to enhance treatment sensitivity and delay tumor progression in patients who are resistant to hormone ablation therapy. In the treatment of tumors that require hormones for growth, clinicians use hormone ablation therapy to inhibit the production of the primary hormone (e.g. testosterone or estrogen) required for tumor growth. While tumors often regress initially following hormone ablation therapy IGFBP-2 or IGFBP-5 make available to the tumor an alternate hormone, insulin-like growth factor-1, or IGF-1, that facilitates continued tumor growth. By inhibiting the production of IGFBP-2 and IGFBP-5, the tumors access to IGF-1 is reduced and tumor growth is delayed.

IPSCIO Record ID: 344567

License Grant
Licensor grants
For the Development License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Profit-Share Territory, and an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Royalty Territory.

For the Commercialization License, an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology to Commercialize Licensed Products in the Field in the Territory.

For the Manufacturing License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Manufacture or have Manufactured Licensed Products for Development and Commercialization in the Field for the Territory.

License Property
Patents includes, among other
RNAI Modulation of RSV and Therapeutic Uses Thereof,
Inhaled Treatment for RSV,
Methods and Compositions for Prevention or Treatment of RSV Infection,
Model for RSV Infection,
Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences,
Use of Double Stranded RNA For Identifying Nucleic Acid Sequences That Modulate the Function of a Cell, and, Influenza siRNA Molecules, Expression Constructs. Compositions. and Methods of Use.

Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

ALN-RSV01 is a synthetic double-stranded RNA (dsRNA) oligonucleotide formed by the hybridization of two partially complementary single-strand RN As in which the 3 ends of each strand are capped with two thymidine units (dT).

ALN-RSVO1 drug product is formulated as a sterile phosphate-buffered solution for dilution with normal saline prior to administration.

Licensed Products means any RNAi Product directed to RSV.

RSV means all strains of the respiratory syncytial virus.

RSVOl Product means any product containing Licensors proprietary composition known as ALN-RSVO1.

RSV02 Product means any product containing Licensors proprietary composition designated by the JSC as ALN-RSV02.

Field of Use
ALN-RSV01 is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients, as well as several other potent and specific second-generation RNAi-based RSV inhibitors in pre-clinical studies.

Directly Competitive Product means any therapeutic or prophylactic product that specifically targets RSV. For avoidance of doubt, Directly Competitive Product as to a Party shall not include a product with broad antiviral activity that may also target RSV as long as any Development of such product as a treatment or
prophylaxis of RSV in humans has been limited to discovery, research and preclinical Development work up to, but not including, IND-enabling studies.

Licensee will develop and commercialize such therapeutic RNA interference products for the treatment of respiratory infections in humans caused by RSV, throughout the world, excluding Japan and certain other countries in Asia.

IPSCIO Record ID: 314354

License Grant
By this amendment, the Parties now proceed with unilateral development of OGX-011 and Products.  As of the Amendment Effective Date, the original Collaboration is terminated.

Licensor grants the Canadian Licensee a worldwide, nonexclusive license, with the right to grant sublicenses, under the Licensor Core Technology, Core Technology Patents, Manufacturing Technology and Manufacturing Patents to research, develop, make, have made, use, gain regulatory approval, commercialize, sell, offer for sale, have sold, export and import OGX-011 and Products for all uses.

For Development, Commercialization and Regulatory Responsibilities, Licensee will have sole responsibility, including without limitation sole responsibility for all funding, resourcing and decision making, for all further development and commercialization with respect to OGX-011 and Products.

License Property
Licensor is discovering and developing RNA-targeted therapeutics, and have created an efficient and broadly applicable drug discovery platform leveraging our expertise in antisense oligonucleotide therapeutics.

OGX-011 is a second generation antisense inhibitor of Clusterin.  Clusterin means the gene target, official symbol CLU, which is also referred to as Testosterone Repressed Prostatic Message -2 (TRPM-2), and Sulphated Glycoprotein2 (SGP-2).

Licensors Core Technology includes the patents and excludes the Manufacturing Technology and Product-Specific Technology.

Field of Use
Licensee is a development stage enterprise committed to the development and commercialization of new cancer therapies. The product candidates OGX-011, OGX-427 and OGX-225 focus on mechanisms of treatment resistance in cancer patients and address treatment resistance by blocking the production of specific proteins which it believes promote survival of tumor cells and are over-produced in response to a variety of cancer treatments.

IPSCIO Record ID: 367331

License Grant
Licensor hereby grants to Canadian Licensee (a) an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology to research, develop, make, have made, use, sell, offer for sale, have sold and import Products, (b) a non-exclusive, worldwide license under the Licensor Core Technology Patents, solely to research develop, make, have made, use, sell, offer for sale, have sold and import Products and (c) a non-exclusive, worldwide license under the Licensor Core Technology Patents solely to research MOE Gapmers generated under the Research Plan that modulate Collaboration Gene Targets. The licenses granted to Licensee are sublicensable only in connection with a license of a Product to one or more Third Parties for the continued development and commercialization of Products in accordance with the terms of this Agreement.  This license will automatically terminate with respect to any Product that modulates a Collaboration Gene Target that has been substituted and replaced by another gene target.
License Property
MOE Gapmer means a single stranded antisense phosphorothioate oligonucleotide of 15-30 nucleotides wherein all of the backbone linkages are modified by adding a sulfur at the non-bridging oxygen (phosphorothioate) and a stretch of at least 10 consecutive nucleotides remain unmodified (deoxy sugars) and the remaining nucleotides contain an O´-methyl O´-ethyl substitution at the 2´ position.

Collaboration Gene Target means Target Slot and any gene target occupying such a slot. Licensee will have a pool (the “Target Pool”) containing up to 2 slots for which Licensee can designate certain gene targets for collaborative research, development and commercialization under this Agreement.

Product means a pharmaceutical preparation comprising any single MOE Gapmer generated under the Project Plan which (i) down regulates a Collaboration Gene Target and (ii) Licensee has provided Licensor with written notice designating such MOE Gapmer as a development candidate.

Product-Specific Technology Patents means all Patents that claim and only to the extent that they claim Product-Specific Technology.

Product-Specific Technology means any discovery, device, process, method of use, composition, formulation, data or information, whether or not patented or patentable, which is made or Controlled solely by Licensor or Licensee, or jointly by Licensor and Licensee, prior to the Effective Date or during the Term of this Agreement, and which relates only to the gene targets down regulated by a Product or in the case of a Discontinued Product, such Discontinued Product.

Licensor Core Technology Patents means Patents Controlled by Licensor on the Effective Date that are necessary for the development and commercialization of the Product, but does not include (A) Licensor’ Product-Specific Technology Patents, or (B) Patents Controlled by Licensor that claim, and only to the extent that they claim, (i) manufacturing and analytical technologies, (ii) formulation and delivery technologies, (iii) RNAi technologies, (iv) microRNA technologies, and (v) other chemical modifications or motifs besides the MOE Gapmer chemistry.

Joint Patents means all Patents that claim, and only to the extent that they claim, Joint Technology.

OGX-011 is a second-generation antisense inhibitor of clusterin and represents the first second-generation anticancer antisense drug based on Licensor's proprietary chemistry to enter clinical development.  Clusterin is a cell-survival protein that is over-expressed in many cancers and is associated with treatment resistance and poor clinical outcome.

Field of Use
Field of use is for the treatment of Cancer.

In preclinical animal studies, OGX-011 improved the potency of traditional chemotherapies by more than 10-fold in prostate cancer with no increase in toxicity. OGX-011 also significantly delayed disease progression in many tumor model systems including in prostate, non-small cell lung, bladder and renal.

IPSCIO Record ID: 344597

License Grant
Included in this license by a Third Party is a sublicense of Licensor intellectual property where the Third Party
— grants a worldwide, exclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Exclusive Field, and,
— grants a worldwide, nonexclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Nonexclusive Field.
License Property
The Third Party designs antisense drugs to treat a wide variety of diseases. Due to their gene selectivity, antisense drugs have the potential to be highly effective and less toxic than traditional drugs, and, owns or has rights in certain technology, know-how, patents and other intellectual property rights related to the design, development, manufacture and/or use of the Products.

Products means an ApoB Product, a GCCR Product and/or a GCGR Product.

ApoB means apolipoprotein B.
ApoB Product means a pharmaceutical composition comprising an ASO that targets ApoB.

GCCR means a glucocorticoid receptor.
GCCR Product means a pharmaceutical composition comprising an ASO that targets GCCR.

GCGR means a glucagon receptor.
GCGR Product means a pharmaceutical composition comprising an ASO that targets GCGR.

The patents are for
Apolipoprotien B-100,
Glucagon Receptor (GCGR) , and,
Glucocoritcoid receptor (GCCR).

Field of Use
The Exclusive Field means human therapeutics, but does not include the Nonexclusive Field.

The Nonexclusive Field means manufacturing (including analytical methods) ASOs, formulating ASOs, conducting Research on ASOs and/or supplying ASOs solely to conduct Research.

IPSCIO Record ID: 346187

License Grant
Included in this license by a Third Party is a sublicense of Licensor intellectual property where the Third Party
— grants a worldwide, exclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Exclusive Field, and,
— grants a worldwide, nonexclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Nonexclusive Field.
License Property
The Third Party designs antisense drugs to treat a wide variety of diseases. Due to their gene selectivity, antisense drugs have the potential to be highly effective and less toxic than traditional drugs, and, owns or has rights in certain technology, know-how, patents and other intellectual property rights related to the design, development, manufacture and/or use of the Products.

Products means an ApoB Product, a GCCR Product and/or a GCGR Product.

ApoB means apolipoprotein B.
ApoB Product means a pharmaceutical composition comprising an ASO that targets ApoB.

GCCR means a glucocorticoid receptor.
GCCR Product means a pharmaceutical composition comprising an ASO that targets GCCR.

GCGR means a glucagon receptor.
GCGR Product means a pharmaceutical composition comprising an ASO that targets GCGR.

The patents are for
Apolipoprotien B-100,
Glucagon Receptor (GCGR) , and,
Glucocoritcoid receptor (GCCR).

Field of Use
The Exclusive Field means human therapeutics, but does not include the Nonexclusive Field.

The Nonexclusive Field means manufacturing (including analytical methods) ASOs, formulating ASOs, conducting Research on ASOs and/or supplying ASOs solely to conduct Research.

IPSCIO Record ID: 346186

License Grant
Included in this license by a Third Party is a sublicense of Licensor intellectual property where the Third Party
— grants a worldwide, exclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Exclusive Field, and,
— grants a worldwide, nonexclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Nonexclusive Field.
License Property
The Third Party designs antisense drugs to treat a wide variety of diseases. Due to their gene selectivity, antisense drugs have the potential to be highly effective and less toxic than traditional drugs, and, owns or has rights in certain technology, know-how, patents and other intellectual property rights related to the design, development, manufacture and/or use of the Products.

Products means an ApoB Product, a GCCR Product and/or a GCGR Product.

ApoB means apolipoprotein B.
ApoB Product means a pharmaceutical composition comprising an ASO that targets ApoB.

GCCR means a glucocorticoid receptor.
GCCR Product means a pharmaceutical composition comprising an ASO that targets GCCR.

GCGR means a glucagon receptor.
GCGR Product means a pharmaceutical composition comprising an ASO that targets GCGR.

The licensed patents are for
Apolipoprotien B-100,
Glucagon Receptor (GCGR) , and,
Glucocoritcoid receptor (GCCR).

Field of Use
The Exclusive Field means human therapeutics, but does not include the Nonexclusive Field.

The Nonexclusive Field means manufacturing (including analytical methods) ASOs, formulating ASOs, conducting Research on ASOs and/or supplying ASOs solely to conduct Research.

IPSCIO Record ID: 346188

License Grant
Included in this license by a Third Party is a sublicense of Licensor intellectual property where the Third Party
— grants a worldwide, exclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Exclusive Field, and,
— grants a worldwide, nonexclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Nonexclusive Field.
License Property
The Third Party designs antisense drugs to treat a wide variety of diseases. Due to their gene selectivity, antisense drugs have the potential to be highly effective and less toxic than traditional drugs, and, owns or has rights in certain technology, know-how, patents and other intellectual property rights related to the design, development, manufacture and/or use of the Products.

The Products means an ApoB Product, a GCCR Product and/or a GCGR Product.

ApoB means apolipoprotein B.
ApoB Product means a pharmaceutical composition comprising an ASO that targets ApoB.

GCCR means a glucocorticoid receptor.
GCCR Product means a pharmaceutical composition comprising an ASO that targets GCCR.

GCGR means a glucagon receptor.
GCGR Product means a pharmaceutical composition comprising an ASO that targets GCGR.

The licensed patents are for
Apolipoprotien B-100,
Glucagon Receptor (GCGR) , and,
Glucocoritcoid receptor (GCCR).

Field of Use
The Exclusive Field means human therapeutics, but does not include the Nonexclusive Field.

The Nonexclusive Field means manufacturing (including analytical methods) ASOs, formulating ASOs, conducting Research on ASOs and/or supplying ASOs solely to conduct Research.

IPSCIO Record ID: 203296

License Grant
For the Non-Exclusive Research License to Licensors Base Technology,  Licensor grants a non-exclusive, world-wide license under the Base Technology and Collaboration Technology to conduct research and Development activities with respect to Targets, Hits, Research Compounds, Lead Compounds and IND Candidates pursuant to the Research Plan.   Licensor also grants the right to sublicense or transfer the rights granted to Licensee under the Collaboration Technology to  Affiliates; and to Third Parties.
License Property
The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient.  The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.

Licensor is a biopharmaceutical company which is focused on the discovery, development and commercialization of small molecules which target post-transcriptional control of protein expression, and which owns certain proprietary technologies for developing small molecule drugs by targeting such post transcriptional control mechanisms, including GEMS.

GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.

Gene Expression Modulation by Small-molecules (GEMS) is PTC’s novel and proprietary screening technology for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology modulate gene expression by targeting the post-transcriptional control processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules.

Field of Use
The Field shall mean the prevention, treatment or diagnosis of all diseases or conditions in humans or animals.

Parties wish to collaborate on specific therapeutic targets with a focus on cardiovascular, metabolic and addictive diseases, and the discovery of clinical candidate small molecules which act upon such targets.
This agreement pertains to drug discovery.

IPSCIO Record ID: 239003

License Grant
The Parties entered into an exclusive worldwide license or sublicense, as applicable, under the Licensee Antisense Patent Rights, to practice Antisense Technology and to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Antisense Products.  Licensee and its Subsidiaries shall have the right to grant sublicenses under the license from Licensor set forth to third parties only to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Licensee Antisense Drugs.
License Property
Antisense Technology shall mean the use of any oligonucleotide or oligonucleotide analog or mimic thereof targeted to a specific sequence of RNA that hybridizes to such sequence and through such hybridization modulates the production of the targeted gene product. The term Antisense Technology shall not include Ribozyme Technology.

US Antisense Patents
5,929,226 – Antisense oligonucleotide alkylphosphonothioates and arylphospohonothioates
5,652,355 – Hybrid oligonucleotide phosphorothioates
6,143,881 – Hybrid oligonucleotide phosphorothioates

Antisense Products shall mean oligonucleotides or oligonucleotide analogs or mimics thereof targeted to a specific sequence of RNA that hybridize to such sequence and through such hybridization modulate the production of the targeted gene product. The term Antisense Products shall not include Ribozymes.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 300745

License Grant
Licensor grants the Japanese Licensee a license under and to Licensor Technology to Develop and Commercialize the Licensed Product in the Field in the Licensee Territory. Such license is exclusive for the Royalty Term of the Licensed Product in each country in the Licensee Territory, and shall thereafter be a non-exclusive, fully-paid license to Develop, Manufacture and Commercialize the Licensed Product in the Field in such country.

For the Manufacturing License, Licensor grants a non-exclusive license under Licensor Technology solely for the purpose of Manufacturing the Licensed Product for the Licensee Territory and Licensee grants Licensor a non-exclusive license under Licensee Technology to Manufacture the Licensed Product.

License Property
Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus (RSV) that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

Antisense Product means a single-stranded oligonucleotide or analog thereof having a specific sequence that inhibits protein synthesis at the nucleic acid level by specifically binding to the sequence of a messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing selective inhibition of gene expression.

The patents include, but are not limited to; RNA interference is mitigated by 21 and 22nt small RNAs;  RNA interference mediating small RNA molecules;  RNA sequence-specific mediators of RNA interference; and, Inhaled treatment for RSV.

Field of Use
Licensee enters this agreement for the treatment of respiratory infections in humans caused by RSV, in Japan and certain other countries in Asia.
RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract.

IPSCIO Record ID: 289255

License Grant
For the LNP Technology, Canadian Licensor will grant to Licensee a non-exclusive right to use the Licensor Combined Licensed Technology and the Category 1 Patents for use in developing and commercializing Supplemental Field Products. The license granted to Licensee supersedes and replaces the licenses granted to Licensee by Party A and Licensor in the current Supplemental Agreement. Licensee’s right to sub-license will be on a Sublicensable Product-by-Sublicensable Product basis.
License Property
LNP intellectual property for use in RNAi therapeutic products using LNP technology.

LNP technology relates to where RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically. LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Licensor’s LNP platform is being utilized in multiple clinical trials.  LNP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models.

RNAi Product means a product containing, comprised of or based on siRNA, Dicer Substrates, Multivalent RNA, or any derivatives thereof, which are effective in gene function modulation and designed to modulate the function of particular genes or gene products by causing degradation through RNA interference of a Target mRNA to which such siRNAs or siRNA derivatives or moieties are complementary. For greater clarity, an RNAi Product shall not include Antisense.

siRNA means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference mechanism that consists of either (a) two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b) a single oligomer of native or chemically modified RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin.

Supplemental Field Product means a product containing, comprised of, or based on Antisense or Gene Therapy.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals.

Field of Use
Field of Use means the delivery of an RNAi Product for any and all purposes.

Supplemental Field means the delivery of (i) single-stranded oligonucleotides, either chemically modified or unmodified, acting through the RNase H mechanism or by or other mechanisms of translational arrest but excluding RNA interference involving RISC (“Antisense”) and (ii) DNA plasmids or messenger RNA (mRNA) either chemically modified or unmodified that are transcribed and/or translated into protein and wherein the pharmacological activity is dependent on expression of the protein (Gene Therapy).

IPSCIO Record ID: 289256

License Grant
Licensor will grant to Canadian Licensee a non-exclusive license to any Licensor Intellectual Property for use in RNAi Products.
License Property
Licensed Product means any product, good, or service covered by a claim of the Licensor controlled Intellectual Property or Licensee controlled Intellectual Property.

RNAi Product means a product containing, comprised of or based on siRNA, Dicer Substrates, Multivalent RNA, or any derivatives thereof, which are effective in gene function modulation and designed to modulate the function of particular genes or gene products by causing degradation through RNA interference of a Target mRNA to which such siRNAs or siRNA derivatives or moieties are complementary. For greater clarity, an RNAi Product shall not include Antisense.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals.

LNP intellectual property for use in RNAi therapeutic products using LNP technology.

LNP technology relates to where RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically. LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Licensor’s LNP platform is being utilized in multiple clinical trials.  LNP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models.

siRNA means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference mechanism that consists of either (a) two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b) a single oligomer of native or chemically modified RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin.

Supplemental Field Product means a product containing, comprised of, or based on Antisense or Gene Therapy.

Field of Use
Field of Use means the delivery of an RNAi Product for any and all purposes.

Supplemental Field means the delivery of (i) single-stranded oligonucleotides, either chemically modified or unmodified, acting through the RNase H mechanism or by or other mechanisms of translational arrest but excluding RNA interference involving RISC (“Antisense”) and (ii) DNA plasmids or messenger RNA (mRNA) either chemically modified or unmodified that are transcribed and/or translated into protein and wherein the pharmacological activity is dependent on expression of the protein (Gene Therapy).

IPSCIO Record ID: 248305

License Grant
The English Licensor hereby grants to Licensee and its Affiliates, a non-exclusive, world-wide, sublicensable license under the Licensed Intellectual Property to (i) use, sell, offer for sale, make, have made, import, export and otherwise dispose of Licensed Products in the Licensed Field and (ii) to engage in the research, screening, discovery, development and testing in connection with the Licensed Products in the Licensed Field. The License expressly ex.eludes Licensees and its Affiliates provision of any services to third parties; production and/or sale of kits, diagnostic products or research reagents; products for non-human animal health, agriculture or other industrial applications outside of the Licensed Field.
License Property
Licensed Intellectual Property shall mean US Patent Numbers 8,097,710, 8,258,285, 8,263,569, 8,299,235 and 8,349,607 and US Patent Application Serial Numbers l I/OJ 3,53 l and 12/508,476 and any patents issuing thereupon, including any continuations, divisionals, continuations-in-part, substitutions, reissues, re-examinations, renewals, continued prosecution applications, foreign counterparts and/or extensions of any of the foregoing.

8,097,710 – Gene silencing
8,258,285 – RNA molecules and vectors for gene silencing
8,263,569 – Gene silencing
8,299,235 – RNA molecules and vectors for gene silencing
8,349,607 – Gene silencing

SRM shall mean a short RNA molecule or molecules nominated by Licensee hereof.  Such SRM will be designed to target and modify the expression of a human gene or genes, where such human gene or genes may be any genes selected from across the human genome and may contain a single short RNA molecule or the combination of rwo such short RNA molecules. Such SRM may comprise an SRM series to provide for lead drug candidate and back-up drug candidate (including different formulations, siRNA sequences or siRNA modifications) addressing the same human gene target. Without limitation to the foregoing and for purposes of clarity, an SRM may comprise short RNA molecules designed to target a combination of two (but no more than two) separate gene targets in the human genome.

Field of Use
Licensed Field shall mean the diagnosis, prevention and treatment of disease in humans.

IPSCIO Record ID: 263910

License Grant
The University grants the Israeli Licensor a co-exclusive, world-wide license to make, have made, use, have used, import, sell, have sold, and offer for sale Licensed Products in the Field of Use during the Term.
License Property
The technology relates to microRNA sequences.  The patents are for Anti Micro-RNA Oligonucleotide Molecules;  Pancreatic Islet MicroRNAs and Methods for Inhibiting Same;   DNA Virus MicroRNAs and Methods for Inhibiting Same; and,  Human MicroRNAs and Methods for Inhibiting Same.
Field of Use
The term Field of Use means human and animal therapeutics.

MicroRNAs have been shown to hold tremendous potential as a new class of prospective drug targets with significant therapeutic opportunity.

MicroRNAs (miRNAs) are a recently discovered, naturally occurring form of RNAi. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNA expression levels have been shown to be correlated with various disease states and to hold great potential as diagnostics and prognostic markers

Licensee's lead therapeutic development program for liver cancer (hepatocellular carcinoma or HCC) has so far identified four microRNAs that when inhibited in vitro lead to a decrease in liver cancer cell proliferation.

IPSCIO Record ID: 369309

License Grant
Universities grant an exclusive, worldwide license to make, have made, use, sell, have sold, offer for sale, import, and otherwise obtain or provide Licensed Products and to use Technology in the Field of Use.
License Property
The patents include
3,4-Dideoxyn Phosphatidylinositol Ether Lipid Analog Inhibitors of Myo-Inositol Cycle;
Deoxy Phosphatidyl Inositol Analogs with Anti tumor Activity;
3-Substituted 3-Deoxy-Phosphatidyl Myo-Inositol Inhibitors of PTEN; and,
Inositol Ether Lipid Analogs and Methods of Using Same.
Field of Use
The Field of Use means any and all fields of use, including the fields of drug design, drug discovery, pharmaceuticals, therapeutics, and diagnostics.

Licensee is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.